Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India
Globally efforts are underway to shorten the existing 6-month tuberculosis (TB) treatment regimen for drug-sensitive patients, which would be equally effective and safe. At present, there is a lack of evidence on the cost implications of a shorter 4-month TB regimen in India. This economic modeling...
Main Authors: | Malaisamy Muniyandi, Nagarajan Karikalan, Banurekha Velayutham, Kavitha Rajsekar, Chandrasekaran Padmapriyadarsini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Tropical Medicine and Infectious Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2414-6366/7/10/288 |
Similar Items
-
The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB
by: Malaisamy Muniyandi, et al.
Published: (2023-08-01) -
Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
by: Laura Rosu, et al.
Published: (2023-11-01) -
Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
by: Abdul Wahid, et al.
Published: (2022-09-01) -
Update of drug-resistant tuberculosis treatment guidelines: A turning point
by: Elisa Vanino, et al.
Published: (2023-05-01) -
Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial
by: Nakwon Kwak, et al.
Published: (2022-08-01)